April 26, 2024 - OLN

Olin Corporation: The Silent Transformation Hiding in Plain Sight

The market seems content with Olin Corporation (OLN). The specialty chemicals and ammunition giant recently announced a quarterly earnings beat, sending ripples of satisfaction, but not waves of excitement, through the investor community. However, a closer look at the available data reveals a quiet revolution brewing within the company, one that could significantly impact its valuation and long-term trajectory.

While analysts focus on Olin's year-over-year quarterly revenue decline of 11.3% [Olin Q1 2024 Results], a deeper dive into the company's financial reports and historical share data exposes a crucial trend: aggressive share buybacks. Olin has been steadily and strategically reducing its outstanding shares, embarking on a path of silent transformation. This trend, largely overlooked amidst the quarterly noise, hints at a company preparing for a future of increased earnings per share and enhanced shareholder value.

The Shrinking Share Count

Let's delve into the numbers. Looking at Olin's outstanding shares history, a clear pattern emerges. In the first quarter of 2022, outstanding shares stood at 159 million. Fast forward to the recent quarter (2024-Q1), and this number has shrunk dramatically to 122 million. That's a reduction of 37 million shares in just two years, representing nearly a 23% decrease in outstanding shares.

The Power of Buybacks

This aggressive buyback strategy signals a powerful statement from Olin's leadership. It suggests a firm belief in the company's intrinsic value and a commitment to boosting shareholder returns. While revenue growth may be experiencing headwinds, this aggressive reduction in shares outstanding will mathematically inflate earnings per share, a metric closely watched by investors.

Consider this: Olin's diluted EPS (TTM) currently stands at $2.81. If we hypothetically assume Olin maintains its current earnings power and continues this aggressive buyback strategy, reducing shares outstanding by another 10% to approximately 110 million, the diluted EPS (holding earnings constant) would jump to $3.12, an 11% increase.

"Hypothetical EPS Growth Through Buybacks"
Shares Outstanding (Millions)Diluted EPS (TTM)
122 (Current)$2.81
110 (Hypothetical)$3.12 (+11%)

Looking Beyond Revenue

Furthermore, this share buyback spree presents a compelling argument against focusing solely on the recent quarterly revenue dip. Revenue, in this case, becomes a less reliable indicator of Olin's overall performance. The shrinking denominator (shares outstanding) creates a potent lever, amplifying the impact of even modest earnings growth.

A History of Resilience

Olin's history adds another layer to this intriguing narrative. Founded in 1892, the company has weathered countless economic cycles and industry shifts. This track record of resilience, coupled with its current strategic focus on enhancing shareholder value through buybacks, suggests Olin is not simply navigating a temporary revenue dip; it is undergoing a calculated transformation, positioning itself for a stronger, more profitable future.

Wall Street's Blind Spot?

The market, it seems, hasn't fully grasped the implications of this silent transformation. While Wall Street analysts offer a target price of $62.19, the potential for significant EPS growth driven by buybacks could propel Olin's valuation beyond current expectations.

An Intriguing Opportunity

For investors seeking value in a volatile market, Olin Corporation presents an intriguing opportunity. The company's quiet revolution, fueled by aggressive share buybacks, is a compelling narrative, one that could rewrite the market's perception of this chemical and ammunition powerhouse. While the market fixates on revenue fluctuations, astute investors might find a silent windfall brewing within Olin's calculated transformation.

"Fun Fact: Olin Corporation is a key supplier of chlorine, a vital component in producing polyvinyl chloride (PVC), a widely used plastic found in everything from pipes and flooring to medical devices and packaging."